Vitrakvi savings card: as little as $0 a prescription with commercial insurance

How to pay the least

Ask for the cash price

Vitrakvi

We didn’t find one.

Ask your pharmacy for Vitrakvi’s cash price, and one or two other pharmacies too.
Vitrakvi’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Bayer US Patient Assistance Foundation. Effective January 1, 2025, the financial eligibility requirement is 300% Federal Poverty Limit (FPL) for most Bayer prescription medications. Or call 1-866-228-7723.

See if you qualify

Compare every option

Brand nameVitrakvi

Authorized genericlarotrectinib

Regular genericlarotrectinib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Vitrakvi?

The original

–

Brand nameThe maker’s card

VITRAKVI $0 Co-Pay Program

Savings card from Bayer

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a prescription

The card takes up to $25,000 a year off your co-pay.

In the maker’s words

“Eligible patients may pay as little as $0 and save up to $25,000 per year.”

From the maker’s offer on vitrakvicopaysupport.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Vitrakvi itself, from the same company, sold without the brand name, and usually for less. For now Vitrakvi is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Solid tumors with an NTRK gene fusion

What the FDA label says

VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:

have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
are metastatic or where surgical resection is likely to result in severe morbidity, and
have no satisfactory alternative treatments or that have progressed following treatment.

Select patients for therapy based on an FDA-approved test.

Source: the FDA label for Vitrakvi (Bayer HealthCare Pharmaceuticals Inc.), May 22, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/vitrakvi/